In advanced breast cancer, around 65% of all HR-positive breast cancer patients respond well to endocrine therapy [5, 6], whereas patients that are ER positive and PR negative (ER+/PR−) have significantly worse prognosis [7–9]. This evidence concerns the gene ESR1 and breast cancer.